SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (2486)9/11/2010 3:29:19 PM
From: Jeffry K. Smith  Respond to of 3027
 
Thanks for your reply. Very interesting!

"PS - I have friend named Jeffery Smith, but he is not in OH. :-)"

And, he spells his name wrong, too! ;-)



To: IRWIN JAMES FRANKEL who wrote (2486)9/13/2010 8:57:01 AM
From: idos  Read Replies (1) | Respond to of 3027
 
Maybe I'm pointing to the obvious but Teva might try to get summary judgment motion itself.
On Copaxone unexpired patents - from what I read, I think the risk from a challenge of "inequitable conduct" is not as high as from "invalidity due to prior art".


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News